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Edited by Masayuki MiyasakaAbstract Enzyme replacement therapy (ERT) has proven to be
an eﬀective therapy for some lysosomal storage disorder (LSD)
patients. A potential complication during ERT is the generation
of an immune response against the replacement protein. We have
investigated the antigenicity of two distantly related glycosi-
dases, a-glucosidase (Pompe disease or glycogen storage disease
type II, GSD II), and a-L-iduronidase (Hurler syndrome, muco-
polysaccharidosis type I, MPS I). The linear sequence epitope
reactivity of aﬃnity puriﬁed polyclonal antibodies to recombi-
nant human a-glucosidase and a-L-iduronidase was deﬁned, to
both glycosidases. The polyclonal antibodies exhibited some
cross-reactive epitopes on the two proteins. Moreover, a mono-
clonal antibody to the active site of a-glucosidase showed
cross-reactivity with a catalytic structural element of a-L-iduron-
idase. In a previous study, in MPS I patients who developed an
immune response to ERT, this same site on a-L-iduronidase was
highly antigenic and the last to tolerise following repeated en-
zyme infusions. We conclude that glycosidases can exhibit
cross-reactive epitopes, and infer that this may relate to common
structural elements associated with their active sites.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Glycosidase; Antigenicity; Epitope reactivity;
Antibody cross-reactivity; Enzyme replacement therapy;
Lysosomal storage disorders1. Introduction
Glycosyl hydrolases (EC 3.2.1–3.2.3) are a diverse group of
enzymes responsible for the hydrolysis of glycosidic bonds.
This hydrolysis occurs by an acid catalysis mechanism, requir-
ing two critical amino acid residues, a proton donor (also
termed acid/base catalyst) and a nucleophile [1,2]. The glycosi-
dases is one the largest subgroups of glycosyl hydrolases and
most members belong to clan GH-A [3,4]. Despite large diﬀer-
ences in size (250–450 residues) and in sequence of the catalytic
domains (<20% identity), families in this clan show a remark-
able conservation in the 3D structure of the active sites [5].*Corresponding author. Fax: +61 8 8161 7100.
E-mail address: douglas.brooks@adelaide.edu.au (D.A. Brooks).
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doi:10.1016/j.febslet.2005.11.053The common catalytic structural element in clan GH-A gly-
cosidases is a (b/a)8-barrel that consists of eight parallel inter-
nal b-sheets and eight outer a-helices [5–7]. Clan GH-A
glycosidases operate with a retaining catalytic mechanism,
which requires the proton donor and nucleophile to be, respec-
tively, located at the C-terminal ends of the fourth and seventh
b-sheets of the (b/a)8-barrel, with a separation of 4.5–5.5 A˚
[2,4,6]. a-L-Iduronidase and a-glucosidase are, respectively,
members of family 39 and 31 of glycosyl hydrolases [5,7].
The key catalytic amino acid residues have been identiﬁed in
human a-glucosidase as aspartic acid 518 (nucleophile) and
aspartic acid 616 (possible proton donor) [8–10] and in human
a-L-iduronidase as glutamic acid 182 (proton donor) and glu-
tamic acid 299 (nucleophile) [4,11,12].
a-Glucosidase and a-L-iduronidase normally function in the
lysosome to, respectively, degrade glycogen and heparan/der-
matan sulfate [13,14]. A deﬁciency in a-glucosidase causes
Pompe disease (glycogen storage disease type II, GSD II),
while a deﬁciency of a-L-iduronidase results in Hurler syn-
drome (mucopolysaccharidosis type I, MPS I). Enzyme
replacement therapy (ERT) has been investigated as a poten-
tial therapy for both MPS I [15,16] and GSD II [17–21] pa-
tients. A potential complication for ERT is the generation of
an immune response to the replacement protein, and this has
been reported in both of these patient groups [15–21]. In
GSD II patients 83% have been reported to develop an
immune response to ERT (http://www.worldpompe.org/myo-
zyme260405.html) and some patients have developed neutral-
izing antibodies to a-glucosidase [17]. In MPS I patients, an
immune response to a-L-iduronidase has been observed in up
to 90% of ERT treated patients [15].
It was postulated that the conservation of structural features
and amino acid motifs in the active sites of glycosidases using a
retaining catalytic mechanism may result in some common
antigenicity. The present study aimed to deﬁne the immune
reactivity of two distantly related human glycosidases, a-gluco-
sidase and a-L-iduronidase.2. Materials and methods
2.1. Materials
Polyvinylchloride plates (96 well) were purchased from Costar
(Cambridge, MA, USA). Non-protein binding microtest plates (96
well, ﬂat bottom) were purchased from Interpath Services (Sydney,blished by Elsevier B.V. All rights reserved.
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Fig. 1. Epitope reactivity of a-glucosidase (A; on a-glucosidase
peptides) and a-L-iduronidase (B; on a-L-iduronidase peptides) poly-
clonal antibodies. Epitope reactivity was expressed as ELISA OD units
(y-axis) and was shown for individual peptide pins (x-axis). Black bars
denote high aﬃnity antibody reactivity.
88 R. Kakavanos et al. / FEBS Letters 580 (2006) 87–92NSW, Australia). a-Glucosidase and a-L-iduronidase peptide pins
were synthesised by Chiron Mimotopes (Clayton, Vic., Australia)
and purchased in a 96-well format. Ovalbumin, bovine serum albumin
(BSA) and ABTS substrate were obtained from Sigma (St. Louis,
MO). Aﬃgel-10 was from Bio-Rad (Richmond, VA, USA). Peroxidase
labelled sheep anti-mouse and anti-human immunoglobulin G (heavy
and light chain) and peroxidase labelled donkey anti-sheep/goat immu-
noglobulin G (heavy and light chain) were purchased from Chemicon
Australia Pty. Ltd. (Boronia, Vic., Australia). The monoclonal anti-
bodies 43D1, 118G3, and 81D3 were a gift from Pharming B.V. (Lei-
den, The Netherlands) while 43G8 was produced in our laboratory (K.
Umpathysivam) and were each produced against puriﬁed a-glucosi-
dase. The polyclonal antibodies to a-L-iduronidase and a-glucosidase
were raised against puriﬁed proteins (expressed in CHO-K1 cell lines)
and aﬃnity puriﬁed against the respective protein as described for
another polyclonal antibody [22].
2.2. Determination of linear sequence epitopes on a-glucosidase and
a-L-iduronidase
Peptide pin technology (ChironMimotopes, Clayton, Vic., Australia)
was used to determine the linear sequence epitope reactivity of anti-a-
glucosidase and anti-a-L-iduronidase antibodies, as previously de-
scribed [23]. Brieﬂy, individual 12 amino acid peptides across either the
a-glucosidase or a-L-iduronidase proteins were synthesised onto poly-
ethylenepins [24].A six aminoacidoverlapbetween consecutive peptides
was used to avoid splitting of linear sequence epitopes. The array of pep-
tide pins (in a 96-well format) was subjected to an ELISA to quantify lin-
ear sequence epitope reactivity. In deﬁning antibody epitopes we have
assumed a single antibody interaction per 12 mer peptide. The level of
ELISA reactivity with each individual peptide is therefore a crude
measure of antibody aﬃnity. Absorbances of 0–0.699 OD units were
deﬁned as little or no reactivity, absorbances of 0.7–2.499 OD units
were deﬁned as low aﬃnity reactivity andODunits greater than 2.5 units
were deﬁned as high aﬃnity reactivity. All reactivities were expressed
relative to control tests with no added primary antibody.
2.3. Alignment and sequence analysis
Relying on known 3D-structures of glycosyl hydrolases from clan
GH-A, we have previously used the 2D-hydrophobic cluster analysis
(HCA) method to predict the active site features and motifs of several
human lysosomal glycosidases, including a-L-iduronidase [4,25]. More
recently, we have also reported experimental evidence supporting the
predicted role of glutamic acid 182 (proton donor) and glutamic acid
299 (nucleophile) in the catalytic mechanism of a-L-iduronidase [11].
Thus, as a-glucosidase was thought to belong to the 4/7 superfamily
of glycosyl hydrolases, we have used a similar bioinformatics approach
(involving sequence analysis and the folding-deciphering 2D-HCA
method) to investigate the structural features and amino acid motifs
of its active site [5].3. Results
3.1. Epitope reactivity of a-glucosidase and a-L-iduronidase
polyclonal antibodies
The epitope reactivity of an a-glucosidase polyclonal anti-
body was deﬁned against the full length a-glucosidase peptide
sequence (Fig. 1A). High aﬃnity reactivity was demonstrated
with a number of peptides across the a-glucosidase protein se-
quence, particularly in peptides 30–120 that were expected to
contain the catalytic (b/a)8-barrel structural element. The a-
glucosidase polyclonal antibody tended to show low level epi-
tope reactivity corresponding to the peptides containing the
active site residues (located at the end of b-strands forming
the (b/a)8-barrel) but higher epitope reactivity to adjacent sites
(located in the a-helical structures connecting the b-strands in
the barrel). A similar pattern of epitope reactivity was
obtained with an a-L-iduronidase polyclonal antibody, against
the a-L-iduronidase protein sequence (Fig. 1B). There was a
trend for the high aﬃnity reactive epitopes located on the ﬁrsthalf of the a-L-iduronidase protein sequence (which has been
shown to correspond to the (b/a)8-barrel) to map to the outer
a-helix elements [4]. However, this trend was less than
previously reported for sera from MPS I patients, who showed
high immune reactivity to a-L-iduronidase in response to ERT
[23].
3.2. Epitope reactivity of monoclonal antibodies to a-glucosidase
and a-L-iduronidase
The monoclonal antibody 43D1, to a-glucosidase, demon-
strated high aﬃnity reactivity with peptides 86 (PFDGM-
NIDMNEP) and 87 (IDMNEPSNFIRG) on the
a-glucosidase protein sequence (Fig. 2A). This indicated reac-
tivity with the IDMNEP sequence, and that the epitope con-
tained the nucleophilic aspartic acid residue of a-glucosidase,
which was predicted to localise to the b4 sheet of the (b/a)8-
barrel. The monoclonal antibody, 43D1, also demonstrated
low aﬃnity reactivity with peptide number 61
(PFMPPYWGLGFH) on a-glucosidase. Another monoclonal
antibody to a-glucosidase, 118G3, demonstrated reactivity
with peptide number 61 and low aﬃnity reactivity with a num-
ber of other peptides across the a-glucosidase protein
(Fig. 2B). The monoclonal antibody 43G8, to a-glucosidase,
showed no epitope reactivity and was presumed to react with
a conformational epitope (data not shown). The monoclonal
antibody 81D3, to a-glucosidase, demonstrated high aﬃnity
reactivity with peptide 20 (QGLQGAQMGQPW) on the a-
glucosidase protein sequence (Fig. 2C). The latter epitope
was located at one of the known proteolytic processing sites
on a-glucosidase [26]. The monoclonal antibody ID1A, to
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Fig. 2. Epitope reactivity of the anti-a-glucosidase monoclonal anti-
bodies 43D1 (A), 118G3 (B) and 81D3 (C). The level of ELISA OD
units (y-axis) was plotted against the peptide pin numbers (x-axis).
Black bars denote high aﬃnity antibody reactivity. The epitope
reactivity of 81D3 was similar to that detected for two other
monoclonal antibodies, which were also generated to a-glucosidase
(data not shown).
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Fig. 3. Epitope cross-reactivity of an a-glucosidase polyclonal anti-
body (A) and the a-glucosidase monoclonal antibody 43D1 (C) when
tested against a-L-iduronidase peptide pins. Epitope reactivity of an a-
iduronidase polyclonal antibody when tested against a-glucosidase
peptides (B). The y-axis shows the level of ELISA OD reactivity
plotted against the peptide pin numbers (x-axis). Black bars denote
high aﬃnity antibody reactivity.
R. Kakavanos et al. / FEBS Letters 580 (2006) 87–92 89a-L-iduronidase, was previously epitope mapped to peptide 72
on the a-L-iduronidase protein (PQGPADAWRAAV, [27]).
3.3. Epitope cross-reactivity of a-glucosidase and
a-L-iduronidase antibodies
An a-glucosidase polyclonal antibody demonstrated strong
cross-reactivity with peptides 19 (YNFTHLDGYLDL) and
83 (PVFPTAEQFRRM) from the a-L-iduronidase protein se-
quence (Fig. 3A). These two peptides also showed high aﬃnity
reactivity with the a-L-iduronidase polyclonal antibody
(Fig. 1B), conﬁrming the antigenicity of these sites. Similarly,
the a-L-iduronidase polyclonal antibody showed high aﬃnity
reactivity with peptide 37 (PFGVIVFRQLDG), on the a-glu-
cosidase protein sequence and a lower aﬃnity reactivity with
several other linear sequences (Fig. 3B). Some sequence iden-
tity was noted between peptide 19 on a-L-iduronidase and pep-
tide 37 on a-glucosidase, with a common LDG sequence motif
(Table 1).
The a-glucosidase monoclonal antibody 43D1 also demon-
strated cross-reactivity with multiple epitopes detected acrossthe a-L-iduronidase protein sequence (Fig. 3C). This included
peptides 3, 12, 19, 30, 42, 106 and 108 from a-L-iduronidase.
None of the other a-glucosidase monoclonal antibodies
showed detectable reactivity with the a-L-iduronidase protein
sequence (data not shown). Similarly, three monoclonal anti-
bodies to a-L-iduronidase failed to react with a-glucosidase
protein sequence (data not shown).
3.4. Analysis of antigenic sites showing some sequence identity
From the cross-reactive a-glucosidase and a-L-iduronidase
epitopes, four common amino acid sequence motifs were
recognised: NEP, LDG, PTA and SPAL (Table 1). A search
of the Swiss-Protein database revealed that these sequence
motifs were present in 18 other glycosidases. Although all
four sequences were found in a-glucosidase and a-L-iduroni-
dase, only one or two of the sequences were found in the
other glycosidases. In particular, seven diﬀerent glycosidases
Table 1
Common sequence motifs in glycosidase enzymes
Enzyme EC no. (Family) Sequence Sequence location Function of residues
Lactase-phlorizin hydrolase 3.2.1.108 KFWMTFNEPMYLAWL 1064–1066 Proton donor 1065
3.2.1.62 ALKAYRLDGIDLRGY 1305–1307
Family 1 KFWITLNEPFVIAYQ 1537–1539 Proton donor 1538
b-Glucuronidase 3.2.1.31 SRECKELDGLWSFRA 41–43 b-sheet
Family 2 VMWSVANEPASHLES 450–452 Proton donor 451
b-Mannosidase 3.2.1.25 MTVLFELDGGLNIEK 309–311
Family 2
a-N-Acetyl galactosaminidase 3.2.1.49 KVDMLKLDGCFSTPE 155–157 Nucleophile 156
Family 27
Glucosyl-ceramidase 3.2.1.45 WAVTAENEPSAGLLS 273–275 Proton donor 274 ?
Family 30
a-Glucosidase 3.2.1.20 VIVHRQLDGRVLLNT 226–228
Family 31 DVVLQPSPALSWRSTG 325–328
FPDFTNPTALAWWED 493–495
GMWIDMNEPSNFIRG 520–523 Nucleophile 518
Maltase-glucoamylase 3.2.1.30 PFTPRILDGYLFCKT 558–60 Active site 1422, Nucleophile 1419
Family 31 GMWIDMNEPSSFVNG 1421–1423
Sucrase-isomaltase 3.2.1.48 GLWIDMNEPSSFVNG 1395–1397 Nucleophile 1393, Active site 1396
3.2.1.10
Family 31
Sialidase 1 3.2.1.18 QGSTWSPTAFIVNDG 123–125
Family 33
Sialidase 2 3.2.1.18 VVAQARLDGHRSMNP 79–81
Family 33
a-Mannosidase IIx 3.2.1.1114 LQLQLGLDGHRTLPS 724–726
a-Mannosidase 2C 3.2.1.24 TFFWEGLDGSRVLVH 415–417
Family 38
Epididymis-a-mannosidase 3.2.1.24 RHYSIRPTAGAQEGT 544–546
Family 38
a-Mannosidase 3.2.1.24 STSLKPPTADLFTGV 247–249 A peptide
Family 38 IPRRSWSPALTIENEH 601–604 D peptide
a-L-Iduronidase 3.2.1.76 SYNFTHLDGYLDLL 114–116
Family 39 WNFETWNEPDHHDFD 181–183 Proton donor 182
EGLRAASPALRLGGPG 213–216
LGRPVFPTAEQFRRM 496–498
a-Mannosidase IA 3.2.1.113 GVLFHSSPALQPAADH 77–80
a-Mannosidase IB 3.2.1.113 GLHDEFLDGQRWIED 244–246
Family 47
Hyaluronidase 2 3.2.1.35 WAMELKPTAPPIFTG 25–27
Family 56
90 R. Kakavanos et al. / FEBS Letters 580 (2006) 87–92had an NEP sequence which was always located in the close
vicinity of either a known proton donor or nucleophile resi-
due (i.e., at the end of a b-sheet structure). While these se-
quences were at antigenic sites in some glycosidases, they
were not speciﬁc to glycosidases, implying that the surround-
ing sequence or structure must have also been important
components of the epitope reactivity in a-glucosidase and
a-L-iduronidase.4. Discussion
There are two main catalytic mechanisms that operate in
glycosyl hydrolases, involving either retention or inversion ofthe substrate stereochemistry at the cleavage point [2]. The
retaining catalytic mechanism is conserved within the follow-
ing glycosyl hydrolase families: 1, 2, 5, 7, 10, 11, 12, 13, 16,
17, 22, 30, 31, 32, 33, 34, 35, 39, 42 [3]. The common catalytic
mechanism in these glycosidases correlates with a strictly con-
served (b/a)8-barrel structure and a small but deﬁned level of
sequence identity, which is focused on speciﬁc residues that di-
rectly participate in the catalytic mechanism [4]. This structure
and sequence conservation led us to investigate the possibility
of common antigenicity in glycosyl hydrolases.
We examined the antigenicity of two distantly related glyco-
syl hydrolases, a-glucosidase (family 31) and a-L-iduronidase
(family 39), which are, respectively, deﬁcient in GSD II and
MPS I patients [13,14]. The selection of these glycosidases
R. Kakavanos et al. / FEBS Letters 580 (2006) 87–92 91was in part due to the observation that both have generated
immune responses in LSD patients undergoing treatment by
ERT [15–21]. A high level of epitope reactivity was detected
on both a-glucosidase and a-L-iduronidase, indicating a
number of highly antigenic sites across both proteins. We
attempted to model the positional location of the (b/a)8-barrel
in a-glucosidase and compare this to a previous prediction for
a-L-iduronidase [5], to localise the speciﬁc epitope reactivities
for these two glycosidases. The probable location of some of
the secondary structure elements of the (b/a)8-barrel in a-
glucosidase were identiﬁed, including the b2, b3, b4
(ASP518) and b7 (ASP616) sheets. In these regions of align-
ment and in a-L-iduronidase, it was evident that there was
generally more epitope reactivity in regions containing a-helix
(outer) compared to b-sheet (inner) elements of the (b/a)8-
barrel structure. The incomplete alignment of a-glucosidase
with other glycosidases may be explained by the recent ﬁndings
for the three-dimensional structure of a-glucosidase from
E. coli, which showed an additional a/b domain inserted
between the third b-sheet and a-helix [10].
Despite the inability to completely align the a-glucosidase
and a-L-iduronidase sequences, we were able to show signiﬁ-
cant cross-reactivity for speciﬁc antibodies that were generated
to each of these two glycosidases. This cross-reactivity was
mainly focused on b-sheet elements of the (b/a)8-barrel that
formed the catalytic sites of the two glycosidases. However,
the linear sequence at these sites of cross-reactivity only had
short 3–4 amino acid lengths of sequence identity. These
sequence motifs were found in some but not all glycosidases
and where present corresponded mainly to b-sheet structures
involved in the catalytic mechanism. For example, the NEP
sequence was only detected at proton donor or nucleophile
sites known to be directly involved in the active site of each
glycosidase, and located at the end of b-sheet structures in
the (b/a)8-barrel. Moreover, the monoclonal antibody 43D1
that reacted with the active site of a-glucosidase containing
ASP518, cross-reacted with a similar site on a-L-iduronidase
containing the E182 proton donor, and both sites contained
an NEP sequence. It was likely that the cross-reactive epitopes
identiﬁed, involved to some extent this short sequence identity,
but also structural similarity at these critical sites.
Here we have shown that glycosidases can have common
antigenic sites and in some cases this involved epitopes relating
to the active sites of these glycosidases. One such epitope was
the ﬁrst to react and last to tolerise in several ERT treated
MPS I patients [23]. Moreover, in some Pompe and Gaucher
patients, neutralising antibodies have been implicated in
reduced eﬃcacy of ERT [17,28]. This highlighted the potential
importance of these epitopes in immune response to replace-
ment proteins.Acknowledgements: Pharming B.V. Leiden, The Netherlands kindly
provided the monoclonal antibodies against a-glucosidase. This work
was funded by NH&MRC Program and Fellowship Grant Funding,
a University of Adelaide Postgraduate Scholarship and an M.S.
McLeod Award.References
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